C-Bridge Capital

C-Bridge focuses on growth equity and buyout transactions. It invests across the maturity spectrum in healthcare companies, from later-stage venture to established firms requiring expansion capital or cross-border support.

The firm is exclusively healthcare-focused, with coverage in life sciences (biotech, pharma), medical devices, diagnostics, healthcare services, and digital health. It does not invest outside healthcare.

The firm leverages its cross-border positioning and Chen's network built over decades in U.S.-China healthcare. Its deal flow comes from direct relationships with healthcare companies seeking capital and cross-border expertise, rather than through a formal intermediary network.

C-Bridge Capital primarily makes direct investments in companies. It has not been publicly identified as a limited partner in third-party funds. The firm's strategy is to control or co-lead investments rather than commit capital to external managers.